After finishing at $0.17 in the prior trading day, Biolase Inc (NASDAQ: BIOL) closed at $0.16, down -5.71%. In other words, the price has decreased by -$0.0097 from its previous closing price. On the day, 3538460 shares were traded. BIOL stock price reached its highest trading level at $0.1750 during the session, while it also had its lowest trading level at $0.1600.
Ratios:
Our goal is to gain a better understanding of BIOL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.68 and its Current Ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, The Benchmark Company on June 19, 2019, initiated with a Speculative Buy rating and assigned the stock a target price of $2.
On April 25, 2017, Singular Research started tracking the stock assigning a Buy rating and target price of $2.50.
WallachBeth Downgraded its Buy to Hold on May 13, 2014, whereas the target price for the stock was revised from $4 to $2.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIOL now has a Market Capitalization of 3.13M and an Enterprise Value of 14.48M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.11. Its current Enterprise Value per Revenue stands at 0.29 whereas that against EBITDA is -0.94.
Stock Price History:
The Beta on a monthly basis for BIOL is 0.65, which has changed by -99.52% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, BIOL has reached a high of $47.10, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.3916, while the 200-Day Moving Average is calculated to be 2.8426.
Shares Statistics:
The stock has traded on average 4.97M shares per day over the past 3-months and 18.1M shares per day over the last 10 days, according to various share statistics. A total of 32.52M shares are outstanding, with a floating share count of 30.69M. Insiders hold about 5.64% of the company’s shares, while institutions hold 4.58% stake in the company. Shares short for BIOL as of Feb 29, 2024 were 245.56k with a Short Ratio of 0.05, compared to 96.56k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.28% and a Short% of Float of 1.28%.
Earnings Estimates
Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$0.81 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$1.42, while EPS last year was -$18. The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.08 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$0.4 and -$3.09 for the fiscal current year, implying an average EPS of -$1.74. EPS for the following year is -$0.09, with 1 analysts recommending between -$0.09 and -$0.09.
Revenue Estimates
3 analysts predict $10.8M in revenue for the current quarter. It ranges from a high estimate of $11.4M to a low estimate of $10.49M. As of the current estimate, Biolase Inc’s year-ago sales were $10.47M, an estimated increase of 3.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $14.76M, an increase of 3.30% over than the figure of $3.20% in the same quarter last year. There is a high estimate of $15.7M for the next quarter, whereas the lowest estimate is $13.79M.
A total of 3 analysts have provided revenue estimates for BIOL’s current fiscal year. The highest revenue estimate was $53.8M, while the lowest revenue estimate was $52M, resulting in an average revenue estimate of $53.07M. In the same quarter a year ago, actual revenue was $49.16M, up 7.90% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $57.21M in the next fiscal year. The high estimate is $57.21M and the low estimate is $57.21M. The average revenue growth estimate for next year is up 7.80% from the average revenue estimate for this year.
